Lymphoma Clinical Trials in Pennsylvania

Showing 481-500 of 564 trials

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

NCT00193492

The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.

Lymphoma, Follicular

SCRI Development Innovations, LLC60 participantsStarted Sep 2005

Jonesboro, Arkansas, United States • Fort Myers, Florida, United States • Jacksonville, Florida, United States +19 more locations

COMPLETEDPhase 195 miles

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

NCT00085150

RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed or refractory leukemia or lymphoma.

LeukemiaLymphoma

National Cancer Institute (NCI)40 participantsStarted Apr 2004

Atlanta, Georgia, United States • Baltimore, Maryland, United States • Bethesda, Maryland, United States +2 more locations

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Lymphoma Trials in Other Cities

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Other Conditions in Pennsylvania